Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis
真实世界临床实践中一线雷莫芦单抗联合厄洛替尼治疗EGFR L858R突变型非小细胞肺癌的疗效和安全性：一项回顾性多中心REAL-SPEED分析
期刊:JTO Clinical and Research Reports
影响因子:3.5
doi:10.1016/j.jtocrr.2026.100972
Ishihara, Masashi; Kawamura, Takahisa; Namba, Yukiko; Takeyasu, Yuki; Hasegawa, Yukihiro; Sato, Yuki; Negi, Yoshiki; Oba, Tomohiro; Sumi, Toshiyuki; Hirata, Hirokuni; Funabashi, Hidemitsu; Oya, Yuko; Kikuchi, Hajime; Tachihara, Motoko; Nakatani, Takeshi; Harada, Taishi; Tanimura, Keiko; Nakagawa, Taku; Takeda, Naoya; Asami, Takahiro; Honjo, Osamu; Nagashima, Hiromi; Yamaura, Takumi; Hata, Norihiko; Kitazono, Miyako; Nishioka, Naoya; Tamiya, Akihiro; Sakamori, Yuichi; Shigaki, Ryota; Kaira, Kyoichi; Honda, Ryoichi; Matsui, Takashi; Suzuki, Eriko; Ito, Kentaro; Otsuka, Kojiro; Yoshizumi, Yuko; Murakami, Yusuke; Matsuno, Kazuhiko; Inoue, Sumito; Kisohara, Akira; Kusumoto, Sojiro; Aoshima, Hiroe; Kakizaki, Yumiko; Kubo, Akihito; Hata, Akito; Ishikawa, Nobuhisa; Hamai, Kosuke; Kanaji, Nobuhiro; Mamesaya, Nobuaki; Misumi, Toshihiro; Matsutani, Noriyuki; Seki, Nobuhiko
